Overview

Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Status:
Completed
Trial end date:
2010-03-09
Target enrollment:
0
Participant gender:
All
Summary
This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:

- Treated with eptacog alpha (NovoSeven®)

Exclusion Criteria:

- Investigator decision to measure for antibody as unnecessary medical testing